申请人:Imperial Chemical Industries Plc
公开号:US05223505A1
公开(公告)日:1993-06-29
This invention concerns novel aminopyrimidinium salts of the formula I: ##STR1## in which R.sup.1 is alkyl, alkenyl, cycloalkyl, phenyl, phenylalkyl or cycloalkyl-alkyl; one of R.sup.2 and R.sup.6 is a basic group selected from amino, alkylamino, dialkylamino of up to eight carbon atoms, pyrrolidino, piperidino and morpholino; and the other of R.sup.2 and R.sup.6 is hydrogen, alkyl, alkenyl, alkoxyalkyl, phenyl, phenylalkyl, cycloalkyl or cycloalkyl-alkyl; or both of R.sup.2 and R.sup.6 are basic groups as mentioned above; and R.sup.5 is hydrogen, (1-4C)alkyl or (3-6C)alkenyl; or R.sup.2 is a basic group as mentioned above, and R.sup.5 and R.sup.6 together form alkylene or, together with the appendant carbon atoms of the pyrimidine ring, complete a benzene ring; R.sup.4 is hydrogen, alkyl, cycloalkyl-alkyl, alkenyl, alkynyl or phenylalkyl; or R.sup.4 is an optionally substitutued alkylene or alkenylene linked to the nitrogen atom of the group Q.A.N--, either of which linking groups may thereby completing a ring including two adjacent carbon atoms of Q, the carbon atoms of A and the adjacent nitrogen atom of the group --A.N--; A is a direct bond to the the group --N(R.sup.4)-- or is alkylene or oxyalkylene; Q is a pyridyl, furyl, thienyl or phenyl moiety; and Y is a physiologically acceptable anion; but excluding a number of compounds specified hereinafter. The invention also includes certain closely related anhydro-base derivatives which, like the formula I compounds, possess beneficial effects on the cardiovascular system (and in particular beneficial effects modulated via the sino-atrial node). Also included are pharmaceutical compositions containing the formula I compound (or a related anhydro-base) as active ingredient, and processes for the manufacture of the various novel compounds.
这项发明涉及式I的新型氨基嘧啶盐:其中R.sup.1是烷基,烯烃基,环烷基,苯基,苯基烷基或环烷基-烷基;R.sup.2和R.sup.6中的一个是从氨基,烷基氨基,最多含有八个碳原子的二烷基氨基,吡咯啉基,哌啶基和吗啉基中选择的一种碱性基团;而另一个是氢,烷基,烯烃基,烷氧基烷基,苯基,苯基烷基,环烷基或环烷基-烷基;或者R.sup.2和R.sup.6都是上述提到的碱性基团;R.sup.5是氢,(1-4C)烷基或(3-6C)烯烃基;或者R.sup.2是上述提到的碱性基团,而R.sup.5和R.sup.6一起形成亚烷基或者与嘧啶环的附加碳原子一起形成苯环;R.sup.4是氢,烷基,环烷基-烷基,烯烃基,炔烃基或苯基烷基;或者R.sup.4是可选取代的烷基或烯基与Q.A.N--基团的氮原子相连,这些连接基团可能形成包括Q的两个相邻碳原子,A的碳原子和--A.N--基团的相邻氮原子的环;A是直接连接到--N(R.sup.4)--基团的键或者是烷基或氧基烷基;Q是吡啶基,呋喃基,噻吩基或苯基基团;Y是生理上可接受的阴离子;但不包括下文中指定的一些化合物。该发明还包括某些紧密相关的无水碱衍生物,类似于式I化合物,对心血管系统具有有益效果(尤其是通过窦房结调节的有益效果)。还包括含有式I化合物(或相关的无水碱)作为活性成分的药物组合物,以及用于制造各种新型化合物的方法。